

BD Medication Delivery Solutions	Document No. CCP-STED-001-DOC
Revision: D	Page 1 of 3

EU DECLARATION OF CONFORMITY (DoC)

Manufacturer:	Becton, Dickinson and Company
	1 Becton Drive
	Franklin Lakes, New Jersey 07417
	USA
Manufacturer SRN:	US-MF-000019182
Authorised Representative:	Becton Dickinson Ireland Ltd.
	Donore Road
	Co. Louth
	Drogheda, A92 YW26, Ireland
Authorised Representative SRN:	IE-AR-000007610
Product:	BD PosiFlush™ SP Syringes
Basic UDI-DI:	038290WKCQDZQWJK
Risk Class and Rule:	Class III, Annex VIII, Rule 14

Form No. CBI-058 FRM20 (MDR DoC) | Revision 05

Document: CCP-STED-001-DOC Valid From: 08-Mar-2023 To: 31-Dec-9999 Print Date: 08-Mar-2023 14:20:47 GMT Standard Time

Doc Type: ZRF Status: Relea Doc Part: EN Revision: N/A Usage: Production Usage Version: D

Status: Released EFFECTIVE
Revision: N/A Change #: N/A
Version: D Classification: Confidential



BD Medication Delivery Solutions	Document No. CCP-STED-001-DOC	
Revision: D	Page 2 of 3	

Intended Purpose	BD PosiFlush TM SP Syringes are intended to be used FOR
	FLUSHING ONLY of in-situ peripheral intravenous catheters
	(PIVCs), peripherally inserted central catheters (PICCs),
	central venous catheters (CVCs), and implanted venous access
	ports.
	BD PosiFlush TM SP Syringe is not intended for dry product
	reconstitution, for medication dilution, or where intravenous
	therapy with sodium chloride is indicated.
	BD PosiFlush TM SP Syringe must not be used on a sterile
	field.
Notified Body:	National Standards Authority of Ireland (NSAI)
	1, Swift square
	Northwood, Santry
	Dublin 9, Ireland
	Identification number: 0050
We, as the manufacturer of the device(s) take sole responsibility for and hereby declare that the above mentioned	
product(s) meet(s) the provisions of the following Directives/ Regulation(s):	
• Regulation (EU) 2017/745 of the	ne European Parliament and of the Council on Medical Devices

Conformity Assessment Route:

	EC CERTIFICATE No.: 745.008 Certificate Expiration Date: 20 December 2027
	EC CERTIFICATE No.: 745.008D Certificate Expiration Date: 20 December 2027
☐ ANNEX X Type Examination	EC CERTIFICATE No.: Certificate Expiration Date:
☐ ANNEX XI Part A Production QualityAssurance	EC CERTIFICATE No.: Certificate Expiration Date:
☐ ANNEX XI Part B Product Verification	EC CERTIFICATE No.: Certificate Expiration Date:
☐ ANNEX II & III Technical Documentation	N/A

Common Specifications (CS): Common Specifications have not been issued for this product.

Number: <version year=""></version>	Title:	Full or Partial Application: <justification></justification>
N/A	N/A	N/A

Form No. CBI-058 FRM20 (MDR DoC) | Revision 05



BD Medication Delivery Solutions	Document No. CCP-STED-001-DOC
Revision: D	Page 3 of 3

Devices Covered by this DoC:

SKU#	Device Name	Device Class
306573	BD PosiFlush™ SP syringe CE 3mL	III
306574	BD PosiFlush™ SP syringe CE 5mL	III
306575	BD PosiFlush™ SP syringe CE 10mL	III
306583	BD PosiFlush™ SP syringe EMA 3mL	III
306584	BD PosiFlush™ SP syringe EMA 5mL	III
306585	BD PosiFlush™ SP syringe EMA 10mL	III

Authorised Signatory:		
Name & Title:	John W. Roberts Regulatory Affairs Director Medication Delivery Solutions	
On behalf of:	Becton, Dickinson and Company	
Place of Issue:	BD Franklin Lakes, NJ, USA	
Date of Issue:	02-Mar-2023	
Signature:	DocuSigned by: John W Roberts Signer Name: John W Roberts Signing Reason: I approve this document Signing Time: 02-Mar-2023 10:35:19 AM PST 8B97BB78BFBD4856ABBFB5B27C5A103E	

DECLARATION OF CONFORMITY Revision History:

Version:	Date:	Detailed Change Description:	Prepared by:
D	2 March 20223	Removed India SKUs (30657371, 30657471 and 30657571).	Perrine Clert-Girard
С	10 February 2023	Updated Technical Documentation certificate number.	Perrine Clert-Girard
В	11 January 2023	Corrected page numbering.	Perrine Clert-Girard
A			Perrine Clert-Girard
		compliance.	

Form No. CBI-058 FRM20 (MDR DoC) | Revision 05